STAAR Surgical Company (STAA) Earnings Call Transcript
May 7, 2025
Earnings Call Speaker Segments
Thank you, operator. Good afternoon, everyone, and I appreciate you being with us today. Joining me on this call are Steve Farrell, our CEO; Warren Foust, President and COO; and Deborah Andrews, our interim CFO. We released our first quarter results earlier today through a press release and a Form 8-K. Both the earnings release and the presentation are available on our investor site at investors.staar.com. This call is set to run 1 hour and will feature Q&A for publishing analysts. Those participating via webcast may also submit questions for today's Q&A session by emailing ir@staar.com. Before we begin, please note that we will be making forward-looking statements during today's discussion. Such statements carry risks and uncertainties that could lead actual results to differ materially from what those forward-looking statements express or imply. I urge you to review the disclaimers in today's release and the presentation, along with the disclosures in our SEC filing. Unless the law requires it, STAAR undertakes no obligation to revise these forward-looking statements to reflect later events or actual outcomes. Also, during today's discussion we will reference certain non-GAAP financial measures, including adjusted EBITDA and constant currency sales. Definitions and reconciliations of non-GAAP metrics can be found in today's release and the presentation. For the sake of brevity, and unless stated otherwise, every comparison made on today's call is on a year-over-year basis against the relevant period. Last, a quick reminder that we intend to use our website to disclose material and nonpublic information and to satisfy our disclosure obligations under Regulation FD. Those disclosures will appear in the investor relations section of our website. As a result, investors should monitor our investor website alongside following our press release, SEC filings, and public conference calls and webcast. With that, I'd like to hand the presentation over to CEO Steve Farrell. Steve?
Hello, everyone, and thank you for joining us this afternoon. Speaking as STAAR's recently appointed CEO, I'm very pleased to have this discussion with all of you. Even though I've been a member of the company's Board, it feels like a real privilege to be leading the management team right now, at such a critical juncture for STAAR. The groundwork for this organization's achievements is in place already, and I'm eager to work alongside our stakeholders around the world as we continue pursuing our goal of becoming the top pick for surgeons and patients who want visual freedom. Just as we noted in the earnings release issued today, our performance has to improve, and it will. I'm telling you straight: you'll get openness from me, whether the news is good or bad, while we restore this excellent company to lasting growth that reflects what our brand can earn and how solid it is. We're navigating intriguing times, just as other firms are, but the fundamental forces behind correcting vision with lenses and the uptake of our patented EVO ICL technology remain unchanged. Myopia rates continue climbing across the globe, and a growing number of patients want options that can be undone, are well-established, and deliver top-tier results. As emerging economies grow richer and the middle class expands its appetite for high-end treatments, we think we're well-positioned to keep gaining share. My first 70 days leading the company have gone very well, but there's still more to do before we reach the financial results that our shareholders expect and deserve, and that we know we can deliver. With that in mind, over the past few months we've addressed near-term tactical matters including channel inventory, cost discipline and tariffs, which puts us in position to soon turn our full attention toward more strategic, growth-focused efforts. Here are a few things we've gotten done. First, we simplified the management structure so it works better and runs leaner. As part of that, Warren Foust has been promoted to President, where he'll oversee our day-to-day operations. Warren, who's on this call with me, brings a track record as an industry executive and a knack for solving problems, and he's just as excited as I am about shaking up the market. As part of our fresh management setup, Deborah Andrews is returning as Interim Chief Financial Officer. She served as STAAR's CFO before, and during that time she earned investor confidence by being transparent. The cost optimization and financial initiatives she designed led to a stretch of strong cash flow generation. In addition, we promoted Magda Michna into the newly created position of Chief Development Officer. Magda is heading our revitalized push to broaden our product portfolio and strengthen the pipeline, and she's already instilled discipline in our R&D work. Together with the full management team, we're dedicated to succeeding in the market and increasing shareholder value. Second, we're collaborating with our China distributors to handle their inventory positions, so that revenue in Q3 lines up more tightly with procedure volume in the market. Brighter times lie ahead, since macroeconomic pressures seem to be easing in China, and we're anticipating a solid back half of the year. Third, in order to reduce potential tariff impacts, we set up consignment arrangements and shipped inventory to our distributors in China on a consignment basis. This is product we still own, it remains on our books, and our distributors are holding it; our belief is that this addresses the bulk of the China tariff problem through at minimum the start of 2026. I'd like to thank the team for moving so fast and decisively to confront this tariff challenge directly. Fourth, we have pinpointed a set of moves to cut costs substantially, among them closing underused facilities and fixed assets, savings in marketing, and reductions in headcount. We think these steps will put us in position to finish 2025 with an SG&A run rate of roughly $225 million. The way we approach trimming expenses is designed to boost our top-line goals rather than restrain them, and each dollar spent or invested will be handled as though it belonged to us personally. This effort to become leaner, focused largely on waste within our U.S. business, positions us to produce strong cash flow down the road once revenue picks back up in Q3. Fifth, we're directing company resources toward expansion efforts in our worldwide business, including Asia Pacific, which is our largest market. With that in mind, I'd like to express gratitude to Wei Zhang, who serves on our Board, for taking on the role of Interim Chief of APAC Strategy. Allow me to take a moment to walk through what we're observing regarding ICL demand in China. One important point from this call is that demand within China is picking up. In Q1 of 2025, we saw ICL procedures improve — that refers to sell-through to hospitals by our two distributors — following a soft second half of 2024. China sales we reported for this year's first quarter totaled just $389,000, since both distributors drew down inventory they already had instead of buying from us. For comparison, China reported sales in last year's first quarter reached $38.5 million. Even though our reported revenue dropped dramatically compared to last year, we're still optimistic. We think in-market ICL procedures during Q1 2025 were about the same as—or maybe even a bit higher than—Q1 2024. And we're still on schedule to get back to more typical reported sales in China beginning in Q3, just like we planned. In Q3, we expect to recognize the $27.5 million in sales linked to the Q4 2024 order from one of our distributors in China. Like we said before, we didn't recognize revenue on that order when it shipped, but we will recognize it once payment comes in. On our Q4 earnings call, we said we believed that keeping these ICLs inside China might assist with the difficulties and holdups tied to importing and logistics, and might also lessen possible effects from geopolitical risk and tariffs. Given how tariffs stand right now, I'd say we're fortunate, maybe even somewhat lucky, that this inventory sits in country. In a brief span, the team has achieved a great deal, and that makes me proud. Now I'll pass it to Warren, who will take us through additional details on how we're responding to China tariffs, along with the newest update on bringing our EVO+ lens to that market. Warren?
Thank you, Steve, and hello to everybody. It's a genuine pleasure to join all of you on this call for the very first time. A few observations regarding tariffs. Back in April, when China responded with retaliatory tariffs on goods from the U.S., we acted fast; we collaborated with our Chinese distributors to establish consignment arrangements and got ICLs shipped out before the tariff implementation deadlines arrived. That consigned inventory remains STAAR's property, yet rather than being stored in warehouses in the U.S. or Switzerland, it now sits with our distribution partners in China, which gives surgeons there extra tariff-free product to work with. I'd like to recognize our teams once more, particularly the folks in Switzerland, but truly spanning 3 continents, who accomplished this in less than 3 days. It was a wonderful illustration of how STAAR employees band together and deliver under pressure. Taking into account the inventory our distributors already held plus the consignment stock we've now positioned forward, we think we'll have sufficient ICLs in China to serve most demand through early 2026; our hope is that the tariff situation improves before that point, though we're simultaneously preparing for the long term. That includes expanding our manufacturing capacity in Switzerland, which we expect will let us ship product to China without an extra tariff on goods of U.S. origin. Of course, tariff rules and the levels charged are constantly in flux and tough to predict. In Switzerland we've made excellent headway, and right now we're on the verge of having the certifications and product clearance our facility needs so it can make goods for China and additional markets out of Switzerland. We expect to wrap up full validation and approval during the summer. After we clear that final hurdle, we'll be able to produce EVO ICLs destined for China from both the U.S. and Switzerland. A key point: we're already manufacturing lenses in Nidau prior to being permitted to ship them to market. Switzerland has earned a durable name for itself when it comes to precision engineering, innovation, and quality, and that really drives home the craftsmanship and know-how behind a high-performance product such as EVO ICL. Our Swiss site will be capable of producing more than 300,000 lenses each year by the close of 2026, and over the longer term there's potential to exceed 800,000 lenses per year. Final inspections and certifications remain on schedule for completion in the coming months. Having more manufacturing capacity in Switzerland will give added support to our growth plans going forward. What we've seen is that once surgeons and clinics gain confidence in EVO, clinically as well as economically, they typically raise their usage and bring more patients into the fold. This is especially the case in Asia. There, surgeons have spent years working with our technology, so the EVO brand carries the most weight. We're building that same mix of clinical and economic trust across the globe. That really is the bedrock of what we term the culture of EVO — the outlook and way of working that helps produce steady growth in EVO ICL procedures. In our view, lens-based approaches represent the future of refractive surgery. New players coming into the market reinforce that belief, and they should also help boost awareness and uptake, which benefits us. Our clinical experience with polymer stretches back over thirty years, and it lets us offer a differentiated premium solution that will keep prevailing in the market. And finally, our EVO+ lens technology, which is also called V5, remains on track to gain approval in China, and that's expected later this summer. It's the first new lens we've had in that market in more than 10 years, it provides a larger optical zone, and ophthalmic surgeons and patients have been eagerly anticipating it. We're excited to further extend EVO ICL's position as the standard for lens-based refractive vision correction in this market. Deborah is now going to share additional commentary on our Q1 financial results. Deborah?
Thanks, Warren and Steve, and good afternoon to all of you. I'd like to begin with a few broad remarks regarding sales, profitability, and margins. In the past, this company separated its reporting of net sales from ICL sales. Because revenue tied to our IOLs and other products has shrunk over the years, the gap between net sales and ICL sales has become fairly narrow at this point. Starting with today's report and going forward, our discussion will center on total net sales. More information can be found in the 10-Q we filed today. Total net sales during the first quarter of 2025 came in at $42.6 million, versus $77.4 million in the same period a year earlier. The change in net sales came about because distributors in China made very few purchases as they sold down inventory already sitting in that country, which was partly balanced out by stronger sales growth worldwide outside China. First quarter 2025 sales in China were $389,000, versus $38.5 million during the same quarter last year. Excluding China, net sales for the first quarter of 2025 came to $42.2 million, a 9% increase in sales compared with the year ago quarter. Earnings for this period were dragged down by weaker revenue, a smaller gross margin, and $22.7 million tied to restructuring, impairment and related charges — a figure that covers severance along with operating lease and other impairment costs; those restructuring charges were taken so the business and its operating footprint could be right-sized, with the goal of better profitability over the long run. Excluding those charges, total operating expenses in the first quarter of 2025 came to $62.7 million, a drop of $574,000 compared with $63.3 million in the same quarter last year. Because cost savings initiatives continue to be rolled out by the company in Q2, additional restructuring, impairments and related charges are expected to be reported. On an adjusted EBITDA basis, Q1 2025 came in at a loss of $26.4 million. That compares with a gain of $5.3 million during the same period a year earlier — a swing of $31.7 million, largely attributable to a $33 million decline in gross profit. One thing to keep in mind: over the coming quarters, consignment sales will make up a bigger share of our total net sales. That reflects the consignment lenses shipped to China in April, for which we haven't recognized revenue yet. Once those lenses are sold to our distributors in later quarters, the revenue tied to that consignment inventory will be recognized. STAAR already runs consignment sales in other major markets, and as we've disclosed in our financial filings, those have averaged roughly $20 million a year since 2022. Turning to how each region performed, net sales climbed 9% once China is left out, with the momentum coming from APAC markets beyond China. In the Americas, we saw a 9% increase during the first quarter. EMEA posted 10% growth in that same quarter, while APAC sales, again excluding China, gained 8%. Strong results in the first quarter were supported by Japan, South Korea and India, all of which pitched in. Further down the income statement, gross margin for the first quarter of 2025 landed at 65.8%, versus 78.9% a year earlier. The decline was mostly attributable to a higher per-unit production cost, which stemmed from lower output at our U.S. plants, along with other cost of sales such as period costs tied to building out the company's manufacturing capacity in Switzerland — that combination cut gross margin by roughly 6 points — and bigger reserves for excess and obsolete inventory, which took off about 4 points. For the back half of 2025, our goal is a 70% gross margin, an improvement but still temporarily suppressed, because we anticipate that the elevated per-unit cost and the period costs from bringing Swiss manufacturing up to speed will stick around throughout 2025 given lower production volume and the early inefficiencies that come with new manufacturing. Even so, we'll keep pushing gross margin higher. Once manufacturing at our Switzerland facility is fully ramped and output levels are driven up, we anticipate gross margin coming back into the 75% to 80% range. On our income statement, the $22.7 million of restructuring, impairment and related charges consists of about $9.4 million in cash expense for severance, workforce reduction and consulting during Q1. The remaining $13.3 million covers noncash impairment of fixed assets, operating leases, property right-of-use assets and internally developed software, which also shows up on our statement of cash flows under impairment of fixed assets and operating leases. Now to our balance sheet. As of March 28, 2025, STAAR closed the first quarter holding $222.8 million in cash, cash equivalents and investments available for sale. Looking at Q1, our receivables were 38% lower than they'd been a year ago, and they came down 49% from where they finished 2024. As of March 28, 2025, that receivable figure was $40 million. We'll see cash balances take a short-term dip during Q2 and Q3, but we don't see cash dropping below $140 million before cash flows start getting better in the latter part of the year; we do believe profitability comes back in the second half, and we also expect cash generation to pick up again as we close out 2025. STAAR continues to have zero debt; with that said, I'll turn things back over to Steve. Steve?
Thanks, Deborah. With the press release we put out today, we pulled the company's outlook that had been given on February 11, 2025 — even though we feel good about what we've recently done to reduce tariff exposure, and even with our positive view on business trends both near term and long term. It's harder to predict things when government policy and the economy are uncertain, especially over the short term. Let me spend a moment pointing out a few of the reasons I feel good about what's ahead and why I'm thrilled to be on the STAAR team. To start, by the time Q2 ends, most of our near-term tactical difficulties will have been dealt with. We're keeping a closer watch on inventory in China. Cost controls have been put in place, and the new management team is dedicated and driven. By building up our in-country inventory, we've reduced most of the near-term tariff risk in China, and we think expanding our manufacturing capabilities in Switzerland will let us reduce most of the longer-term risk. Once sales and growth pick back up to higher levels in Q3, the savings from our cost initiatives should show up in the bottom line. The second reason I feel good about what's ahead is that we hold a unique proprietary polymer material along with a first-mover advantage, which gives us a sustainable competitive edge. From a technology standpoint, things work in our favor, and we have a 30-year head start on any new entrants. We have a proven solution, and EVO ICL ought to be the procedure of choice in every market. Our lenses are made from a biocompatible polymer material that stays stable inside the eye and is incredibly hard to replicate, particularly at scale. We think our EVO ICL will turn into the preferred surgical solution, since it's an additive procedure and our lenses get implanted in front of the natural crystalline lens. EVO doesn't harm the integrity of the eye, because it never permanently reshapes the cornea and can be taken out. EVO provides UV protection and better visibility through a quick procedure with a fast recovery. Even though we're only getting started, we think there are chances to apply our proprietary polymer material in other therapeutic areas, particularly within the eye. The third reason I feel good about what's ahead is that we compete in a market that's very large and growing, so tailwinds will generally be at our back, even if that hasn't happened lately. While data on laser vision correction shows procedure volumes overall are falling, ICL procedure volumes are climbing, and we think the total addressable market for lens-based refractive vision correction is a far larger opportunity. Though my evaluation of our current addressable market is still a work in process, I felt it mattered to share some preliminary thoughts on how we view this opportunity. We think the EVO ICL procedure's advantages will eventually make it the obvious pick for vision correction that is refractive worldwide, just as it already is in places such as Japan, where confidence among surgeons runs high, patients know more about ICL as a route other than laser correction, and the market setting has suited ICLs well. The figures aren't flawless, yet MarketScope puts the worldwide refractive surgery sector at close to 5.2 million procedures for 2025, which strikes us as possibly slightly elevated, though it falls within the range we estimate; our individual lenses go for an average of $500 to $600 around the world, yet that amount swings widely, from just below $400 for a lens to beyond $1,200, based on the particular features of the lens and how much is bought. As stated in our press release, during this quarter we managed to broaden our labeling in Brazil, meaning we can now properly serve the whole refractive market worldwide from there. We're working toward label modifications, such as spherical power, in additional major markets across the globe, so that in time we'll hold the clearances needed to take part in the bulk of those 5.2 million procedures. Thus, at the low end, one could frame our opportunity as 5.2 million worldwide refractive procedures multiplied by our ASP of $500 to $600. Still, we feel that way of viewing the market plays down what's possible for us. Our focus historically has been on drawing in surgeons who handle the tiny share of patients choosing a surgical route, encompassing LASIK, PRK, SMILE and our EVO ICL. Yet the vast bulk of individuals with myopia haven't gone the surgical path, choosing instead to remain untreated or to use glasses or contact lenses. About 1/3 of everyone on earth, or 2.7 billion individuals, has myopia right now, and roughly 1.1 billion among them fall in the 21 to 45 age bracket, which is who our EVO ICL technology targets. That works out to 2.2 billion possible procedures. A large number of these individuals might be served with our lens and no label expansion at all. What we must figure out is how to get past the barriers stopping our target group from pursuing visual freedom through EVO ICL. Such barriers take in attempts to retain patients in glasses and contacts, hesitation from surgeons, patients not knowing about it, patients' capacity to pay, and patients' dislike of eye surgery, along with other things. Getting past these barriers won't be easy, and we still lack every solution. Even so, we recognize the need to discover routes to reach the tens of millions of patients who haven't chosen the surgical vision correction path, yet can afford our ICL, and who would gain from the visual freedom our ICL delivers. We're getting the word out regarding EVO, and more surgeons and patients are choosing EVO ICLs for refractive vision correction. Myopia's occurrence is rising around the world, driven by heavy computer and smartphone usage along with less time spent in natural light and fewer outdoor pursuits. This market opportunity has barely been touched by us so far, and expansion is rapid. There is still work ahead, yet our direction gives me confidence. Each quarter, I'm eager to update you on how we're doing and, even more crucially, to produce financial results that prove themselves. Next week, Warren and I will be in Asia to see investors, which includes attending the CICC Investor Conference in Shanghai. Our team is also excited to connect with many of you at the Stifel Ophthalmology Summit, the Wells Fargo West Coast Bus Tour, the William Blair Annual Growth Stock Conference, and the Jefferies Global Healthcare Conference, all coming up soon. We appreciate your attention and your ongoing backing of STAAR. Operator, let's open the line for questions now.
I apologize in case some of this came up during the other calls. But perhaps beginning with China, I'd like to know whether you could share a little more detail about the way ICL sellout performed in 1Q '25. If you could provide any color month by month, that would be excellent; it sounds like perhaps flat to up, but further granularity would be welcomed. Then, any remarks about how 2Q has gone so far, plus early perspective on the summer high season as we get closer to it? And I have a follow-up after that.
Yes. Tom, this is Warren. Wonderful to hear from you, good question. Look, we're happy with the way the year began, especially after the back half of 2024, which was soft; and so regarding your question about the pace of January, February versus March, they were all — end market sales were all pretty steady. So I'm not sure I would draw a distinction among any of the 3 months. But once more, I would simply say, in line with what we said, we were quite pleased with the pace and it gave us an opportunity for the distributors we partnered closely with to burn down some of the inventory that they had built up. So coming out of Q1 in a reasonable spot.
That's excellent, and I'm grateful for it. Turning now to the topic of competition. Could you perhaps share your thoughts on Eybrite and describe the competitive effect you've observed on ICL up to this point? I realize it's early days still, yet what feedback are you getting from your customers? Do any adoption patterns stand out to you? Also, should we anticipate any approximate revenue effect when it comes to 2025?
Yes, that's a solid follow-up question. Well, things have been quiet. We have definitely inquired with our customers regarding this, and a handful of them possess some familiarity with it. Whenever a new lens enters the marketplace, the provider frequently gives those lenses away free of charge, and they attempt pricing arrangements in order to secure some adoption. Up to now it has simply been immaterial; therefore we more or less embrace competition, we definitely don't dismiss it, yet we just haven't witnessed much uptake; and it might possibly stem from EVO being established for so many years in China and across the globe, but in China — and so we'll continue monitoring it. Without a doubt our teams stand ready for it, but there isn't much to share at this point.
Steve Farrell here. I would add as well that when it comes to the surgical side, we're glad to see competition, since we believe that making more people aware there are choices beyond glasses and contacts is beneficial. In our view, that pie is able to grow, and we see raising awareness around it as something useful over the long run.
Also, Tom, regarding how you and everyone else should approach modeling, plus the latter portion of what you asked—honestly, I'm not in a position to offer any direction on that front. From our perspective, it simply isn't significant. We had already factored it into our initial plans; so once more, we'll stay attentive to it, though things have remained fairly calm up to this point.
Appreciate those questions, Tom. Brian Moore here, from STAAR Surgical. On the STAAR management side, we've got a question sent in by someone on the webcast. Let me go ahead and read it. "Just like numerous other businesses did during this quarter, you pulled your guidance owing to the tariff circumstances and economic uncertainty; however, you likewise signaled that procedure trends in China have gotten better and that your cost reduction efforts are paying off. So does that imply that, assuming economic trends across the globe don't worsen from this point, on the current picture — the current picture appears stronger than what STAAR communicated back in February."
Yeah, absolutely — I appreciate the question. There's obviously a fair amount of uncertainty around the world right now. On tariffs, we're taking steps to reduce the impact, but the situation keeps shifting; and honestly, we don't have full clarity on what the final target even looks like. We're putting in serious effort to get ahead of it, though it's a moving picture. On top of that, we're still working our way through inventory. And like you pointed out, things are going well when it comes to costs. That said, we have a fresh team and a fresh playbook. Warren, Deborah, and I need to be sure — or close to sure — that we'll deliver whatever we promise you. Do we believe we've got a solid chance of reaching our guidance? Yes, we do. Still, we hold ourselves to a tougher bar than a solid chance; we need to be sure or close to sure. As a team, we're dedicated to being transparent with investors, and we're dedicated to helping investors view the business the same way we do. That means we truly need to lay out our thinking for you and guide you as you consider what lies ahead; so allow me to attempt that; we aim to win your trust, and we believe nothing works better for earning that trust than delivering strong results. So let me handle the guidance question piece by piece. I'll begin with sales ex China. A couple of months back, the outlook was $165 million to $175 million in revenue along with $40 million per quarter across the first 2 quarters. Naturally, we landed Q1 at $42.5 million in revenue. And when it comes to global sales ex-China, we grew 9%, and our full-year range spans 9% to 15%. So can we reach the 9% to 15%? Yes, I'd say we have a solid chance. Is that the way we want to engage with investors? — not exactly. We want to be sure about the guidance we hand you; so with the $165 million to $175 million guidance, do we have a chance of landing inside it? It's a fairly solid chance. Yes, I believe so. Now turning to China. China is rebounding fast. We guided $75 million to $125 million. Do I believe we'll reach that? Yes, I feel quite confident about reaching it. And so we are — we feel quite good when it comes to China. Now turning to gross profit, we guided to 70% gross profit. We fell short of that in Q1 by a little. But I believe we have strong reasons for that shortfall. And I believe those reasons will ultimately boost shareholder value over the long run; we're scaling up our Switzerland facility. That will assist us with tariffs, it will assist us with our overall supply; and strategically speaking, it's a fantastic decision. Over the near term, our fixed costs are simply too high relative to the number of units we're producing. From a facilities standpoint, we need to operate efficiently, and those facilities must run nearer to capacity before we can return to that 75% or 80% level. Will we reach it? Absolutely, we'll get there eventually. Will it happen within this year? Most likely not. So when you're building long-term models, I'd say the 75% to 80% range is a very solid range for us. At this moment, though, we are ramping, and that ramp is speeding up. We believe that serves shareholders' best interests, but does it place our 75% gross margin for the year somewhat at risk? Indeed, it does. Turning to operating expenses, our guidance on the SG&A line was $212 million to $288 million. As of today, we've announced that the $225 million range looks good to us. That means we'll land at the low end of that range, which I consider a positive, and we're operating efficiently there, so we've provided some commentary on that front. Then I'll move to the final element of guidance, our cash, and we announced today that we might fall to $140 million. We're quite confident we won't go below that figure. That compares with exiting the year at $150 million to $175 million. Do we believe that remains a solid outlook for cash at year-end? Certainly. However, there's a long distance between where we stand now and that point. Regarding adjusted EBITDA, our guidance was for a loss of approximately $30 million; we actually came in ahead of that, at $26.4 million, so we feel fairly good, particularly given our cost controls, that we will achieve the EBITDA outlook. Still, the key message for investors here is that we're dedicated to being transparent with you; we'd like you to view the business the way we do; we're enthusiastic about the business. And we don't want to find ourselves in a situation where something beyond our control occurs and makes us look bad; this is a new administration, and we aim to earn your trust, which we believe is best accomplished by delivering results.
Congrats on the recent appointments, and I hope things go smoothly for you in the rest of the year. Could you say a little more about what was mentioned regarding China and consignment inventories as a means of lessening the impact from tariffs tied to the global trade war? Can you put a number on how much inventory is held in the channel through consignment? And as we think about — I know it's a bit early — heading into 2026, where more mitigation steps might be needed, maybe you could take us through the big-picture approach for how that could play out, and then I'll ask a quick follow-up.
Yes. Anthony, good to hear from you. So what we've said is that we've got enough inventory on hand to offset the impact of tariffs until about the close of this year and into 2026. What I think we mentioned previously is that on the owned side, we were carrying too much stock. Because of that, ahead of the tariffs, a couple of our distributors were sitting on some extra inventory, and our plan was to let them work that down during this year by selling into the market, and the market has performed well, so that's a positive. As a result, we expect to hit the inventory levels required under our contracts around the midpoint of this year. That's meaningful headway, and we feel good about it. Actually, the fact that the inventory ended up in China is something we feel good about, and it only took a handful of days — as you said, our team deserves some of the recognition here. We got just 3 days' notice, and we actually had staff from the U.S. on-site at the facility; we were able to pull them away from the room where our new ERP system is being rolled out, bring them over to the warehouse, and get them working. They felt really good about being asked to help. They volunteered their own time and helped out, which allowed us to stack inventory onto pallets, get it onto planes, all within that 3-day window, and then have it delivered to our distributors in China. So it took a 3-continent effort to put consignment agreements in place so that inventory would be there; that will carry us through this year; and it also gives us the opportunity to build inventory at our Swiss facility, which we're ramping up now. You heard me mention that we're waiting on internal validations and external approvals; we feel confident about those. And those efforts to build inventory before we receive those approvals should put us in the best position to mitigate. So I think that's kind of part 1 and part 2 of your question because it gives us — the next effort to mitigate is going to be the reduction in the tariffs. That's not something we can forecast with any confidence. So our approach is to think long term, and to serve that demand we're accumulating inventory in Switzerland.
That's quite useful. As a follow-up, perhaps we could get a current perspective from the company regarding pricing strategy — on a worldwide basis, even. How is the team currently leaning when it comes to setting prices for Visian ICL in China, and possibly also in the United States? Has there been any significant shift in the way leadership approaches global pricing?
Yeah, that's a fair question. Nothing major has shifted. EVO ICL is something patients adore. In over 99% of cases, they tell us they'd choose it again. That tells us the benefit EVO ICL delivers both to the people who receive it and to the surgeons who implant it is extremely high. Naturally, we'll keep examining ways to drive growth alongside our customers. Pricing may always play some role in that effort, yet it isn't the primary driver. What actually fuels a patient's want for this is the worth of the device and the difference it makes in someone's life. So we'll keep exploring options, though our confidence in this product's value remains firm.
Stephen, there's something I'd like to get clear on, and really this isn't so much a question — you're discussing figures for the year, yet you pulled guidance. I'm just a bit puzzled about what you're actually telling us regarding where those figures might land or might not, now that guidance has been withdrawn.
I'm not certain I'm tracking what you're asking.
Alright, it seems like you're describing what you believe you're capable of achieving, yet at the same time you're pulling your guidance. So honestly, I'm having trouble squaring those two things. That might come across more as an observation than an actual question, though I'm not sure whether you'd like to respond to it. Anyway, that's…
Absolutely, thank you, Ryan, I understand now. What we're attempting to do is provide a bit of insight into our thinking. Transparency is what we're aiming for here; therefore, the response is that this constitutes a conversation, which in my view differs somewhat from official guidance. And so we — I believe one point you picked up on during that conversation was that outside of China, growth came in at 9%. The range we've given is 9% to 15%. A conclusion you ought to have drawn is that reaching 15% is something we're somewhat concerned about; consequently, we'd prefer to have this conversation with you at this point and be open rather than discover at year-end that we landed at 8.5% and have all of you frustrated with us. So what we're doing is offering insight into where we believe the business can go; and additionally — I believe it was clear in what I said that hitting the gross margin guidance for this year likely won't happen, since our Switzerland manufacturing is being scaled up. So creating confusion is not our aim. I'm sorry if that's what occurred. Being transparent and helping you grasp how we view the business is what we're after.
Perhaps that's on my end. My apologies. I see the goal you're pursuing, yet it lands in a way that may leave me puzzled. Allow me to pose something more basic. Warren, you mentioned a version 5 heading into China; that's the initial time we've caught wind of it. In what ways does it vary from EVO+? And what about the price gap — assuming there is one — a tiered pricing approach inside China?
Yeah. My bad for any muddle there. The product is one and the same. People frequently call EVO+ that, in fact, within the company; V5 is the name used. So those terms are everywhere, it's identical. So nothing differs on that front, we've been indicating we'd secure V5 — or pardon me, EVO+ at some stage in 2025 near the middle of the year. We think we're on schedule for that, when it comes to approval. We're still weighing the commercial opportunity regarding pricing, especially given what has occurred most recently on tariffs. We obviously must factor in every consideration. We think it will carry a premium. That's also what our customers think, based on the responses they've given us. Ultimate choices still need to be made on that, so keep watching. Ultimate choices about the volume and the customers we'll launch with, so keep watching. Once approval arrives, we'll set those plans, though our confidence is fairly high.
All right, and I just want to get a handle on — apologies for all of these inquiries. There are many moving pieces in play here, Stephen, that you're taking on with the business. You've got inventory levels in China. You mentioned returning to the third quarter, a sales cadence that's more normalized, roughly speaking. You also now have this consigned inventory in China. But if the market doesn't recover as fast as you'd like, and the sell-out rate stays flat because of global macro conditions, a recession, or something else, then how do you think about the inventory levels and the consignment in China stretching beyond around early '26? Since logically, those would get pushed out even further if your distributors can't bring that demand down. And maybe this gets at — the question gets at what you've managed to do since you took over to see things more clearly in China, so this doesn't become yet another problem again.
Sure. Good question. So to be clear, we own the consignment inventory in China. So it's essentially the same situation as keeping it in a California warehouse — it simply goes through the tariff procedure. That stock is therefore equivalent to inventory stored domestically. From a distributor's standpoint, then, no excess problem arises. The second half of your question, I believe, was about what happens if it doesn't sell.
Yeah, that's roughly what I'm getting at.
The way we move through those inventory levels, and once it turns, by the time next month wraps up, we'll be sitting at the levels our contracts call for. So from an inventory standpoint, we're going to reach that point, since we're practically there right now; and really, once next month ends, on average across China, we'll be right at contractual levels.
I'd like to pick up where Ryan left off regarding China. Leadership changes have been made for STAAR there, so can you walk us through how the new people in charge are shaping your wider approach in that country, particularly since conditions at the macro level appear to be getting better there? Also, Stephen, I understand formal guidance isn't being given anymore, yet you don't seem to be backing away from the earlier China guidance. Could you describe the recovery speed you're anticipating there across the year? And what gives you confidence that you'll land within that original range?
Hi, Simran, Warren here. Let me take the China topic first, then check whether Steve wants to chime in, and he can handle the other one. We've got an excellent team across Asia. Specifically in China, our people are highly seasoned. Training and working alongside our distribution partners is something they excel at — the team we've built there makes us very proud. When it comes to leadership, Asia brings in the largest revenue of any part of the company, naturally. Measured by dollars and units, China ranks as the single most valuable country. Because of that, our leadership — especially at senior levels — ought to be based in that region. That's essentially the rationale behind the strategic choice we took. As we've shared publicly, we're fortunate to have Wei Jiang come aboard, stepping into a China leadership role on somewhat of an interim basis as APAC Head of Strategy; he's a highly capable individual. He's a proven leader with deep regional experience, extending beyond China, and he grasps how to operate there through the local language and customs. He's genuinely assisting us — I'd call it not merely a double click but a triple click on identifying where the opportunities lie, where success has occurred and can be repeated, and where difficulties have arisen and can be resolved; we're thrilled about what he, along with the team he's bringing, contributes to China, though it doesn't alter the basic fact that the right people are already on the field for us there in China.
Okay, so regarding the second portion of what you asked — how quickly things are bouncing back. We’re aware that ICL procedures have risen compared with a year ago. Compared with Q4, the increase is dramatic. Nearsightedness keeps becoming more common. Only this morning, the Chinese government said it would lower rates across the board. By the time next month ends, our inventory will have been cleared. So for us in China, everything seems to be heading the right way toward a solid second half of the year.
Okay, that's useful. And for my follow-up, about those cost reductions you're making — it looks like the focus is mostly on the U.S. operation, and you mentioned inefficiencies and spending there. Can you say more about what those inefficiencies actually were? And what does this tell us about your approach in the U.S., or your wider dedication to the U.S. opportunity over the longer term?
Yes, I'll give it a try, Simran. That's a fair question. The U.S. matters a great deal to us; it continues to matter a great deal. It's also still a very, very tiny share of our overall worldwide business — and we spent a lot to build traction in the U.S. operation. You could say we've achieved that. There's 11% growth even during the quarter, against what is once again another quarter of — if you talk to the refractive surgery council, they'll say lasers are down almost 15.5%. So there's still a very large gap between the laser market and how we've done in the U.S. So that's something we're proud of; but when you consider the direct-to-consumer marketing, when you consider certain steps we've taken, which are very substantial to grow the organization, to invest heavily in every conference, every meeting. Frequently at the gold and platinum sponsorship level — that doesn't mean we won't sponsor and support; it simply means we have to ensure we take a disciplined approach as we gain growth, but we gain disciplined growth; so resources matter. We're going to keep putting some into the U.S., but we're also going to ensure that we're directing the greatest resources toward the markets that can matter most. A lot of those are in Asia, but we're also seeing success in Europe, especially in certain distributor markets where emerging opportunities are visible. So we'll balance our investments. We'll be disciplined in how we proceed with cuts in the U.S., but we're going to ensure we rightsize the — any given business relative to the revenue we're bringing in.
Absolutely. There are a couple of additional points I want to make. First, a significant portion of our efforts involves getting our facilities to the right size. We currently have space that isn't being fully utilized, and that's something we need to fix. Regarding the reductions, while they aren't minor — that's one way to describe them — what they accomplish is simply returning us to the position we held 18 months back. Our business was performing very well at that time, and we're essentially restoring our SG&A spending to the 2023 run rate. So, are these cuts significant? Yes. However, they aren't so extensive that daily operations will suffer. Eighteen months ago we had a highly successful business, and we're moving back to those SG&A levels.
Understood, that's a big help. And apologies, I just want a fast clarification regarding the tariffs. Do you factor in anything about counter-tariffs taking hold once the 90-day pause ends?
Well, nobody can predict how tariffs will play out. Still, we're positioned quite well all the way to the close of this year. It's possible — should those tariffs remain at 145%, we'd likely need to send certain inventory into China that isn't currently in country. We don't expect it to be material, though we carry thousands of SKUs. So it's possible we'd need to move some inventory into country. On the whole, my sense is that President Trump's strategy, or what he's aiming for, isn't to push us into a worldwide recession. So we're hopeful that we — a fix will get negotiated that sharply lowers those tariffs. Should that fail to occur, we'll be increasing output at our Switzerland facility, and that gives us a safety valve. You might have noticed that the Vice Premier of China and Scott Bessent are getting together in Switzerland, since it's a neutral location — well, that's exactly where we're attempting to establish our manufacturing. So we feel fairly confident about where we stand over the longer term. Operator, we're out of time, but let's take — please unmute the final questioner.
I'll limit myself to just one so we can keep this moving quickly. What's happening in the U.S. is sort of an extension of the investment angle. What's your thinking on the go-to-market approach over there? I understand the investment piece, but there were a number of initiatives. You had Highway 93, and then there was the effort around helping surgeons with lens selection. Do you believe that strategic approach was correct? Or might that be something you'd ultimately decide to alter?
Yes. Patrick, I appreciate the question. Look, I — we're never content; but I wouldn't claim to be proud of our performance in the U.S. The truth is that 2 years in a row since we began executing some of those strategic initiatives, it's happened against the backdrop of a somewhat soft economy and a laser refractive market that's been challenged. And that's why I think you heard Steve mention that we need to widen our aperture and quit focusing only on laser vision correction procedures and which of those can deliver people into the funnel for us; we need to be talking about how to get folks out of glasses and contacts and into that funnel. So you'll hear us searching for opportunities in that area; but regarding strategic initiatives, the particular ones you mentioned such as U.S. Highway 93 and others. Look, we remain focused on helping our customers become clinically capable. We want them to feel clinically confident. We want them to feel economically confident. And once we achieve that, it genuinely enables them to build a culture within their own practice that says we're EVO ready and we possess an ecosystem that will welcome a patient who might be open to an EVO ICL and can guide them along the path of conversion, which produces a great clinical outcome for that patient. So none of that has changed. The one thing I'd add is that alongside what we've been doing, since U.S. Highway 93 was really just terminology for how we segment and target customers, we direct our limited resources toward customers who can accomplish more with EVO ICL because of their practice economics, because of their readiness to operate on the eye instead of merely using lasers, because they already have a refractive stream of patients coming through the door. Those are all reasons we'd prioritize a given customer. We'll continue doing that. We'll also build pathways, and we've already done so, to bring in other customers who wish to be part of the ICL revolution. They approach us and say, we want to do EVO as well, and we need an onboarding process for them. So we're establishing that pathway, and through their commitment, it lets us invest alongside them. So I'm probably as enthusiastic as I've ever been about the U.S. and what's possible there. From a cost management perspective, we're simply stating that we'll ensure it's appropriately sized moving forward. Operator, I'll hand the call back over to you.
We appreciate it; that wraps up the Q&A portion, and with that, our conference comes to a close as well. Thanks for joining us for today's presentation. Everyone is free to disconnect at this point.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete STAAR Surgical Company transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.
Get an API key View API docs →For developers and AI pipelines
Programmatic access to STAAR Surgical Company earnings transcripts and 132,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $162 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.